Background: Differences in the clinical course of secondary acute myeloid leukemia according to the type of the preceding disorders are not defined. We compared the outcomes of therapy-related acute myeloid leukemia, acute myeloid leukemia following myelodysplastic syndrome and acute myeloiod leukemia following myeloproliferative neoplasm. We also intended to find prognostic factors in secondary acute myeloid leukemia overall. Methods: Retrospective medical record review at Seoul National University Hospital was performed. We assessed response to induction chemotherapy and overall survival. Results: Ninety-five secondary acute myeloid leukemia patients (median age of 56.4 years) were analyzed. Twenty-six, 57 and 12 patients had therapy-related leukemia, leukemia following myelodysplastic syndrome and myeloproliferative neoplasm, respectively. For patients receiving induction chemotherapy, complete remission rate was 47.5% and complete remission rate was different according to the type of the preceding disorders (P ¼ 0.004). Compared to therapyrelated leukemia (P ¼ 0.027) and leukemia following myelodysplastic syndrome (P ¼ 0.050), leukemia following myeloproliferative neoplasm had shorter overall survival. In secondary leukemia, presence of trisomy 8 had a prognostic impact (P ¼ 0.003) along with cytogenetic risk group (P ¼ 0.016). In multivariate analysis, the type of the preceding disorders (P ¼ 0.026), 5q deletion (P ¼ 0.015) and trisomy 8 (P ¼ 0.040) were independent prognostic factors. Conclusions: Prognosis of secondary acute myeloid leukemia was different according to the type of the preceding disorders with the worst prognosis in leukemia following myeloprolfierative neoplasm. Along with cytogenetic risk grouping, trisomy 8 had a poor prognostic impact in secondary acute myeloid leukemia.
INTRODUCTION
Definition of secondary acute myeloid leukemia (s-AML) is not clear and s-AML is rather a heterogeneous disease. Preceding disorders of s-AML are variable and usually include myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN) and exposure to chemotherapeutic agents. karyotype influenced prognosis in German series. And recently, karyotype turned out to be important as a prognostic factor even for s-AML patients who received allogeneic stem cell transplantation (SCT) (3, 4) .
On the other hand, about 30-40% of MDS patients develop AML (5) , and their prognosis is also grave with 3 year survival rate of 8% in one report (6) . It is generally accepted that AML evolving from MDS is chemo-refractory and their prognosis is poor (7) . However, reports regarding prognostic impact of karyotype in AML evolving from MDS are rare. For MDS, clinical impact of specific karyoytpe has been suggested (8, 9) ; however, we cannot assume the same clinical impact would be preserved in AML evolving from MDS.
For AML following MPN, not much is known. So far, most studies focused just on the leukemogenic potential of MPN treatment-anagrelide and hydroxyurea were in the center of this issue (10) . AML evolving from MPN is also known to have extremely poor prognosis, where treatment with cytotoxic agents may not have beneficial effect (11, 12) . However, clinical course and prognostic factors in AML following MPN are not well defined.
To summarize, previous studies focused on s-AML of single etiology, especially, therapy-related AML (t-AML). The studies suggested that prognosis of s-AML is poorer compared with de novo AML and s-AML needs allogeneic SCT for improvement in outcome (13, 14) . However, admitting the fact that prognosis of s-AML is the poorer compared with de novo AML, there is a chance that differences may exist within s-AML according to the type of preceding disorders, that is the differences among t-AML, AML following MDS and AML following MPN. In such a case, differential treatment approach would be applied according to the type of preceding disorders. However, as far as our knowledge, not a single study was performed to evaluate the differences among t-AML, AML following MDS and AML following MPN. Additionally, although prognostic impact of karyotype had been evaluated in t-AML, similar data are lacking for AML following MDS and MPN. Whether the risk group based on karyotyping has prognostic impact in s-AML in general is to be established.
So we planned to compare clinical course of s-AML according to preceding disorder. We also intended to evaluate the impact of karyotype as a prognostic factor in s-AML in general.
PATIENTS AND METHODS

PATIENTS
Ninety-five adult (Age !15 years) patients who were diagnosed as AML with history of preceding hematologic disorders at Seoul National University Hospital between January 1997 and December 2007 were included in this retrospective study. Patients with s-AML arising from MDS, s-AML arising from MPN and s-AML developing after exposure to cytotoxic chemotherapy were included in this study. s-AML arising from therapy-related MDS was considered as t-AML. MPN included essential thrombocythemia (ET), primary myelofibrosis (PMF) and polycythemia vera (PV). Patients with acute promyelocytic leukemia were excluded. Data regarding patient demographics, laboratory profiles, latency period, chemotherapy regimen, chemotherapy response, treatment-related mortality (TRM), first disease-free survival [complete remission (CR-1)] and overall survival (OS) were obtained by medical record review.
For patients who received induction chemotherapy, induction regimens mainly consisted of cytarabine and idarubicin (AId). Standard dose of cytarabine 100 mg/m 2 for 7 days and idarubicin 12 mg/m 2 for 3 days were used for most patients, while dose modification were performed based on general condition of patients at a physician's discretion. Other induction chemotherapy regimens included AD (cytarabine and daunorubicin), FLAG (fludarabine and cytarabine with G-CSF support), MA (mitoxantrone and cytarabine) and MT (mitoxantrone and topotecan).
Followed by induction chemotherapy, consolidation chemotherapy using combinations of idarubicin, daunorubicin and cytarabine or allogeneic SCT was performed after CR according to donor availability with shared decision (15) . Thirteen patients received BMT as a consolidative measure.
Bone marrow biopsy was reviewed and the diagnosis of AML, MDS and MPN was made according to WHO classification 2008 (16) . CR was defined as a normocellular bone marrow containing less than 5% blasts and showing evidence of normal maturation of other marrow elements. Risk grouping based on cytogenetics was performed according to the previous study (2) . Latency period was defined as a duration from diagnosis of MDS/MPN or first chemotherapy to diagnosis of s-AML. OS was calculated from diagnosis to death from any cause. CR-1 was defined as a period from first successful induction chemotherapy to documentation of disease relapse. The study protocol was reviewed and approved by the institutional review board of Seoul National University Hospital. The recommendations of the Declaration of Helsinki for biomedical research involving human subjects were also followed.
KARYOTYPING USING THE CONVENTIONAL G-BANDING METHOD
Conventional cytogenetics was performed on heparinized whole bone marrow samples according to standard protocols (17) . More than 20 metaphase cells per patient were analyzed under the microscope, and the definition of clones and the descriptions of karyotypes were in accordance with the International System for Human Cytogenetic Nomenclature (18) . Inv(9), 14pstkþ and 16qhþ were considered to be normal variants, and thus, not counted as abnormal lesions.
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STATISTICAL ANALYSIS
The variables included for analysis in this study were age, gender, initial white blood cell (WBC) count, platelet (PLT) count, absolute neutrophil count (ANC), preceding disorders before s-AML, cytogenetic analysis result, outcome of induction chemotherapy, CR-1 and OS. Statistical analysis of 2 Â 2 contingency tables of categorical variables were performed using Pearson's x 2 test or Fisher's exact test, as appropriate. t-test or ANOVA was performed for comparison of means as appropriate. Median durations of CR-1 and OS were calculated using the Kaplan -Meier method and comparisons between groups were made using log-rank tests. The impact of continuous numeric variables on clinical outcome was calculated using logistic regression and Cox regression model. Multivariate analysis was performed using a logistic regression model for response and Cox regression models for CR-1 and OS. Factors with P values ,0.1 in univariate analysis were examined with multivariate regression models. All statistical tests were two-sided, with significance defined as P , 0.05. All analysis was performed using SPSS for Windows Version 12.0 (SPSS Inc.).
RESULTS
PATIENT CHARACTERISTICS
This study included 35 females and 60 males with a median age of 56.4 (range: 17.8 -83.8) years. Forty-three patients were above the age of 60. Twenty-six patients had t-AML, 57 patients had AML evolving from MDS, and 12 patients had AML evolving from MPN. MPN included two ET's, six PMF's and four PV's. Among 26 patients with t-AML, 13, 17 and 13 patients were exposed to topoisomerase 2 inihibitors, platinum agents and cyclophosphamide, respectively. Thirteen of 26 t-AML patients received radiotherapy and four of 26 t-AML patients had preceding therapy-related MDS. Median latency period was 14.3 months (range: 0.4 -227.1 months). Among 12 AML patients evolving from MPN, 8 patients received hydroxyurea for NPM. One patient received upfront allogeneic SCT for NPM before development of AML. Eighty-four patients had karyotype result, where 6 patients had favorable risk, 59 patients had intermediate risk and 19 patients had poor risk disease. Patient characteristics are summarized in Table 1 . Among the 14 patients with 5q deletion, 13 patients had concomitant other karyotypic abnormalities. Likewise, 11 among 13 patients with -7/7q deletion and 11 among 21 patients with trisomy 8 had concomitant other karyotypic abnormalities.
When comparison was made according to the type of the preceding disorders, latency period, WBC count, PLT count and risk group were significantly different according to the preceding disorders. Latency period was the longest in AML following MPN (median: 92.6 months) and the shortest in AML following MDS (6.7 months). WBC count was higher in t-AML compared with AML following MDS (P ¼ 0.002).
PLT count was higher in AML following MPN compared with AML following MDS. Presence of complex karyotype, 5q deletion, -7/7q deletion and trisomy 8 was not different according to preceding disorders. However, six patients with favorable risk disease were all t-AML and risk group was significantly different according to preceding disorders (P ¼ 0.001). These differences are summarized in Table 2 .
For patients with t-AML, 11q23 balanced gene rearrangement was found in one patient who had exposure to topoisomerase 2 inhibitor. Latency period was not significantly different according to exposure to topoisomerase 2 inhibitor (34.9 months for patients without exposure vs. 19.1 months for patients with exposure, P ¼ 0.450). Presence of preceding MDS before t-AML was not affected by specific chemotherapeutic agent exposure.
For AML following MPN, further analysis according to type of MPN was not performed due to small number of patients in the each sub-category.
INDUCTION CHEMOTHERAPY OUTCOME, CR-1 AND OS ACCORDING TO THE TYPE OF PRECEDING DISORDERS The study patients were followed up for median of 78.2 months. During follow-up, 83 deaths occurred. Eighty over 95 patients received induction chemotherapy.
The proportion of patients receiving induction chemotherapy was not different according to the type of the preceding disorders (P ¼ 0.619). Of 80 patients who received induction chemotherapy, CR was achieved in 38 patients (CR rate 47.5%) and induction-related mortality occurred in 11 patients (13.8%). CR rate was different according to the type of the preceding disorder with the highest CR rate in t-AML (73.9%) and the lowest CR rate in AML following MPN (18.2%). Induction-related mortality was not significantly different according to preceding disorders (P ¼ 0.062). Proportion of patients receiving SCT as a consolidation was not different according to the type of the preceding disorders (P ¼ 0.076) ( Table 2) .
For patients who achieved CR, CR-1 was not significantly different according to the type of the preceding disorders (P ¼ 0.511) (Fig. 1A) . However, OS was different according to the type of the preceding disorders (Fig. 1B) . OS was the shorter for AML following MPN when compared with t-AML (median: OS 3.9 vs. 8.7 months, P ¼ 0.027) and AML following MDS (median: OS 3.9 vs. 6.6 months, P ¼ 0.050). There was not a significant difference in OS between t-AML and AML following MDS (P ¼ 0.470).
IMPACT OF KARYOTYPE IN S-AML IN GENERAL AND MULTIVARIATE ANALYSIS
CR rate was not affected by karyotypic risk group, presence of complex karyotype, presence of 5q deletion and presence of -7/7q deletion. However, the presence of trisomy 8 predicted lower CR rate (17.6% vs. 53.6%). When multivariate analysis was performed considering the type of the preceding disorder, WBC count and presence of trisomy 8, preceding disorder (P ¼ 0.010) and presence of trisomy 8 (P ¼ 0.023) were independent predictive factors for achievement of CR (Table 2) .
For patients who achieved CR, CR-1 was significantly affected by risk group (P ¼ 0.024) (Fig. 2A) . When specific karyotypic abnormalities were considered, presence of complex karyotype (P , 0.001), 5q deletion (P , 0.001) and -7/7q deletion (P ¼ 0.037) was related to the shorter CR-1 (Fig. 2B -D) . However, when multivariate analysis was performed, not a single parameter was an independent predictive factor for CR-1.
For OS, risk group predicted OS with median OS for favorable, intermediate and poor risk disease 12.5, 7.3 and 4.6 months, respectively (P ¼ 0.046) (Fig. 3A) . When specific cytogenetic abnormalities were considered, presence of complex karyotype (P ¼ 0.010), 5q deletion (P , 0.001), -7/7q deletion (P ¼ 0.020) and trisomy 8 (P ¼ 0.003) predicted short OS (Fig. 3B -D) . 5q deletion was related to adverse prognosis both in t-AML (P ¼ 0.001) and AML from MDS (P , 0.001). Also, trisomy 8 predicted shorter OS in t-AML (P ¼ 0.019) and showed 
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Secondary acute myeloid leukemia tendency for shorter OS in AML following MDS (P ¼ 0.060) (Fig. 4A and B) . When multivariate analysis was performed considering age, type of the preceding disorders, presence of complex karyotype, presence of 5q deletion, presence of -7/7q deletion and presence of trisomy 8, preceding disorder (P ¼ 0.039), presence of 5q deletion (P ¼ 0.015) and presence of trisomy 8 (P ¼ 0.019) were independent prognostic factors (Table 3) . However, when SCT was considered along with pre-treatment factors aligned above, only SCT was an independent prognostic factor (P ¼ 0.025).
DISCUSSION
In this study, we compared the clinical course of s-AML according to its preceding disorders for the first time. AML evolving from MPN had long latency period, low CR rate after induction chemotherapy and poor prognosis compared with the other s-AMLs. The negative prognostic impact was valid both in univariate and multivariate analysis. Although no data compared AML evolving from MPN directly with other s-AML's yet, prognosis of AML from MPN has been reported to be extremely poor. For example, Mesa et al. (11) reported prognosis of MPN is not ameliorated even with induction chemotherapy when compared with best supportive care. Low CR rate in our study coincides with the result by Mesa. However, no plausible underlying mechanism that can explain chemo-refractoriness of AML evolving from MPN exists. So, ex vivo research is necessary not just for explanation but also for the development of future therapeutics in s-AML arising from MPN. Also, evaluating efficacy of SCT in AML from MPN is mandatory.
Besides, AML evolving from MDS and t-AML had similar prognosis. Again, although no study directly compared clinical course of t-AML and AML from MDS yet, long-term survival rate of 20 -30% with SCT has been reported both for t-AML and AML from MDS (3, 19) . Considering the fact that chemotherapy induces myelodysplastic change frequently (20) , we assume that similar pathogenic mechanism would be shared between t-AML and AML evolving from MDS. To summarize, the direct comparison among three s-AMLs in our study implies that treatment approach should be applied differentially at least for s-AML evolving from MPN. We also showed that prior study results regarding karyotype in t-AML can be applicable to s-AML in general. German study showed that risk grouping based on karyotype is applicable to t-AML, but its applicability to s-AML in general was doubtful (2) . In this sense, our result would serve as an evidence that facilitates risk categorization of s-AML based on karyotype. More interesting finding is the adverse prognostic impact of 5q deletion in s-AML in general. 5q deletion was related to adverse prognosis in 
1042
Secondary acute myeloid leukemia univariate and multivariate analysis in our study. Moreover, 5q deletion was related to poor prognosis in AML from MDS, which is contradictory to the favorable impact of 5q deletion in MDS (5) . This suggests that clinical meaning of 5q deletion in MDS and AML from MDS is different. In vitro study is necessary to elucidate the underlying cellular mechanism of this clinical phenomenon. Another novel finding of our study is that trisomy 8 had a poor prognostic role in s-AML. Controversy exists about the role of trisomy 8 even in de novo AML. Cancer and Leukemia Group B study demonstrated that trisomy 8 was related to poor OS, while Southwest Oncology Group and Medical Research Council study did not show prognostic importance of trisomy 8 (21, 22) in de novo AML. Previous German study focusing on t-AML did not show role of trisomy 8 in those population. However, in our study, trisomy 8 was related to poor prognosis both in univariate and multivariate analysis. Also, both in t-AML and AML from MDS, trisomy 8 seemed to be related to poor prognosis, which strongly suggests the negative prognostic impact of trisomy 8. This may be also attributable to distinct characteristics of s-AML in Asian population. However, considering conflicts between results both in de novo AML and t-AML, whether trisomy 8 should be classified as a poor prognostic factor in s-AML needs to be validated in a large-scale prospective study.
On the other hand, we failed to show differences in karyotype and latency period between anthracycline-related t-AML and topoisomerase-related t-AML. We assume this may be attributable to the either of the two following explanations. One explanation originates from an ethnic diversity. It is well known that AML in Asia and Western countries differ especially in cytogenetics and gene mutations. For example, NPM1 mutation and t (8,21) did not show favorable prognostic impact in Asian de novo AML patients (23, 24) . Also, the frequency of specific genetic mutations like FLT3 is different (25) . Moreover, frequency of single nucleotide polymorphism in genes that are suggested to have relationship with t-AML is different between Asian and Westerns (26, 27) . There may be a chance that clinical feature of t-AML is different in Asians compared with Western countries especially in terms of cytogenetics. The other explanation is that clinical difference was not evident due to small number of t-AML patients included in this study. This is also possible because we included only 26 t-AML patients, where subgroup analysis may not have enough statistical power.
Of note, our study showed only phenotypic difference in clinical course of s-AML's according to its preceding disorders and karyotypic abnormalities. Because we could not perform additional genome-wide association study due to retrospective nature of our study, we were unable to suggest genetic abnormalities underlying these phenomena. With additional genome-wide association study such as genomic array hybridization or gene mutation analysis in the future, we hope that genetic aberrancy, which can explain these phenomena would be discovered.
In conclusion, prognosis was different according to the type of the preceding disorder in s-AML with the worst prognosis in AML evolving from MPN. And, trisomy 8 had a prognostic impact in s-AML along with cytogenetic risk grouping.
